These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 30362543)
1. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer. Cui Y; Huang Y; Wu X; Zheng M; Xia Y; Fu Z; Ge H; Wang S; Xie H J Cell Physiol; 2019 Jun; 234(6):8740-8751. PubMed ID: 30362543 [TBL] [Abstract][Full Text] [Related]
2. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer. Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655 [TBL] [Abstract][Full Text] [Related]
4. New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells. Ciocan-Cartita CA; Jurj A; Zanoaga O; Cojocneanu R; Pop LA; Moldovan A; Moldovan C; Zimta AA; Raduly L; Pop-Bica C; Buse M; Budisan L; Virag P; Irimie A; Gomes Dias SM; Berindan-Neagoe I; Braicu C J Exp Clin Cancer Res; 2020 Nov; 39(1):241. PubMed ID: 33187552 [TBL] [Abstract][Full Text] [Related]
5. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR. Wang X; Chen T; Li C; Li W; Zhou X; Li Y; Luo D; Zhang N; Chen B; Wang L; Zhao W; Fu S; Yang Q J Hematol Oncol; 2022 Aug; 15(1):122. PubMed ID: 36038948 [TBL] [Abstract][Full Text] [Related]
6. ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/β-catenin and FAK/Akt/mTOR. Wan H; Li Z; Wang H; Cai F; Wang L Clin Transl Oncol; 2021 Apr; 23(4):902-910. PubMed ID: 32939659 [TBL] [Abstract][Full Text] [Related]
7. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124 [TBL] [Abstract][Full Text] [Related]
8. CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231. Yang M; Li Y; Ruan Y; Lu Y; Lin D; Xie Y; Dong B; Dang Q; Quan C Mol Cell Biochem; 2018 Jun; 443(1-2):169-180. PubMed ID: 29159771 [TBL] [Abstract][Full Text] [Related]
9. STAT3 as a promising chemoresistance biomarker associated with the CD44 Moreira MP; da Conceição Braga L; Cassali GD; Silva LM Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988 [TBL] [Abstract][Full Text] [Related]
10. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133 [TBL] [Abstract][Full Text] [Related]
11. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Blanchard Z; Paul BT; Craft B; ElShamy WM Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261 [TBL] [Abstract][Full Text] [Related]
12. Serum tRNA-derived fragments (tRFs) as potential candidates for diagnosis of nontriple negative breast cancer. Huang Y; Ge H; Zheng M; Cui Y; Fu Z; Wu X; Xia Y; Chen L; Wang Z; Wang S; Xie H J Cell Physiol; 2020 Mar; 235(3):2809-2824. PubMed ID: 31535382 [TBL] [Abstract][Full Text] [Related]
13. Race Disparities in the Contribution of miRNA Isoforms and tRNA-Derived Fragments to Triple-Negative Breast Cancer. Telonis AG; Rigoutsos I Cancer Res; 2018 Mar; 78(5):1140-1154. PubMed ID: 29229607 [TBL] [Abstract][Full Text] [Related]
14. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim. Byerly JH; Port ER; Irie HY Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444 [TBL] [Abstract][Full Text] [Related]
15. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226 [TBL] [Abstract][Full Text] [Related]
16. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. Qin JJ; Yan L; Zhang J; Zhang WD J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482 [TBL] [Abstract][Full Text] [Related]
18. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132 [TBL] [Abstract][Full Text] [Related]
19. Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance. Xia M; Zu X; Chen Z; Wen G; Zhong J Cancer Lett; 2021 Dec; 523():100-110. PubMed ID: 34601022 [TBL] [Abstract][Full Text] [Related]
20. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. Li M; Li A; Zhou S; Lv H; Yang W J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]